# Niacin to Improve Blood Flow in People With Sickle Cell Disease

> **NCT00508989** · PHASE2 · COMPLETED · sponsor: **National Heart, Lung, and Blood Institute (NHLBI)** · enrollment: 30 (actual)

## Conditions studied

- Sickle Cell Disease

## Interventions

- **DRUG:** Niacin-ER
- **DRUG:** Placebo
- **DRUG:** L-NMMA
- **DRUG:** Acetylcholine

## Key facts

- **NCT ID:** NCT00508989
- **Lead sponsor:** National Heart, Lung, and Blood Institute (NHLBI)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-07-24
- **Primary completion:** 2010-12-31
- **Final completion:** 2015-12-24
- **Target enrollment:** 30 (ACTUAL)
- **Last updated:** 2020-09-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00508989

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00508989, "Niacin to Improve Blood Flow in People With Sickle Cell Disease". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT00508989. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*